Literature DB >> 12877575

Transepithelial transport of bepridil in the human intestinal cell line, Caco-2, using a "dynamic model".

F Mathieu1, M J Galmier, A Nicolay, J F Pognat, C Lartigue.   

Abstract

The purpose of the study was to go further into the transepithetial transport of bepridil, an anticalcic agent, through monolayer cells Caco-2, using a "dynamic model" including a transfer of inserts with Caco-2 cells into new wells, free of drug, at regular intervals, in order to simulate the blood flux. The state of cells was evaluated by measuring the transepithelial electrical resistance and the transport of bepridil was followed using a gas chromatography/mass spectrometry determination. This study exhibits the importance of the basolateral renewal both on the transport of bepridil and the maintenance of cells in a satisfactory state. Two elimination phases from the cell compartment seem to occur, with basolateral half lives respectively of 12.2 and 25.6 hours, probably linked with two kinds of cellular binding sites. This dynamic model permits the reflection and simulation of the slowness of the in vivo absorption of bepridil in the small intestine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12877575     DOI: 10.1007/BF03190505

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  13 in total

1.  Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa.

Authors:  A R Hilgers; R A Conradi; P S Burton
Journal:  Pharm Res       Date:  1990-09       Impact factor: 4.200

2.  In vitro permeability through caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system.

Authors:  S Chong; S A Dando; K M Soucek; R A Morrison
Journal:  Pharm Res       Date:  1996-01       Impact factor: 4.200

3.  Comparison of HT29-18-C1 and Caco-2 cell lines as models for studying intestinal paracellular drug absorption.

Authors:  A Collett; E Sims; D Walker; Y L He; J Ayrton; M Rowland; G Warhurst
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

4.  Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2.

Authors:  G Krishna; K Chen; C Lin; A A Nomeir
Journal:  Int J Pharm       Date:  2001-07-03       Impact factor: 5.875

5.  Transepithelial transport of bepridil in the human intestinal cell line, Caco-2, using two media, DMEMc and HBSS.

Authors:  F Mathieu; M J Galmier; J F Pognat; J Petit; C Lartigue
Journal:  Int J Pharm       Date:  1999-04-30       Impact factor: 5.875

6.  Mechanisms of absorption enhancement by medium chain fatty acids in intestinal epithelial Caco-2 cell monolayers.

Authors:  T Lindmark; T Nikkilä; P Artursson
Journal:  J Pharmacol Exp Ther       Date:  1995-11       Impact factor: 4.030

7.  Regulation of paracellular permeability in Caco-2 cell monolayers by protein kinase C.

Authors:  W F Stenson; R A Easom; T E Riehl; J Turk
Journal:  Am J Physiol       Date:  1993-11

8.  Use of a biophysical-kinetic model to understand the roles of protein binding and membrane partitioning on passive diffusion of highly lipophilic molecules across cellular barriers.

Authors:  T J Raub; C L Barsuhn; L R Williams; D E Decker; G A Sawada; N F Ho
Journal:  J Drug Target       Date:  1993       Impact factor: 5.121

9.  Absorption enhancement of hydrophilic compounds by verapamil in Caco-2 cell monolayers.

Authors:  M Sakai; A B Noach; M C Blom-Roosemalen; A G de Boer; D D Breimer
Journal:  Biochem Pharmacol       Date:  1994-09-15       Impact factor: 5.858

10.  In vitro toxicity and formation of early conjugates in Caco-2 cell line treated with clenbuterol, salbutamol and isoxsuprine.

Authors:  A Stammati; P Badino; I De Angelis; G Re; O Vincentini; C Zanetti; F Zucco; G Brambilla
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Apr-Jun       Impact factor: 2.569

View more
  1 in total

1.  Influence of different calcic antagonists on the Caco-2 cell monolayer integrity or "TEER, a measurement of toxicity?".

Authors:  F Mathieu; M J Galmier; J F Pognat; C Lartigue
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jan-Jun       Impact factor: 2.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.